0001422848-14-000175.txt : 20140812
0001422848-14-000175.hdr.sgml : 20140811
20140808164335
ACCESSION NUMBER: 0001422848-14-000175
CONFORMED SUBMISSION TYPE: SC 13G
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20140808
DATE AS OF CHANGE: 20140808
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: GW PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001351288
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FILING VALUES:
FORM TYPE: SC 13G
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-87941
FILM NUMBER: 141028020
BUSINESS ADDRESS:
STREET 1: PORTON DOWN SCINECE PARK
CITY: SALISBURY WILSHIRE SP4 0JQ UK
STATE: X0
ZIP: 00000
BUSINESS PHONE: 44-1-9-80557-000
MAIL ADDRESS:
STREET 1: PORTON DOWN SCINECE PARK
CITY: SALISBURY WILSHIRE SP4 0JQ UK
STATE: X0
ZIP: 00000
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Capital Research Global Investors
CENTRAL INDEX KEY: 0001422848
IRS NUMBER: 951411037
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: SC 13G
BUSINESS ADDRESS:
STREET 1: 333 SOUTH HOPE STREET
STREET 2: 55TH FLOOR
CITY: LOS ANGELES
STATE: CA
ZIP: 90071
BUSINESS PHONE: 213-486-9200
MAIL ADDRESS:
STREET 1: 333 SOUTH HOPE STREET
STREET 2: 55TH FLOOR
CITY: LOS ANGELES
STATE: CA
ZIP: 90071
SC 13G
1
edggwph.txt
SC 13G
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
GW Pharmaceuticals plc
(Name of Issuer)
Ordinary Shares
(Title of Class of Securities)
36197T103
(CUSIP Number)
July 31, 2014
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP: 36197T103 Page 1 of 5
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Capital Research Global Investors **
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE
INSTRUCTIONS) (a)
(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
5 SOLE VOTING POWER
24,585,840
6 SHARED VOTING POWER
NUMBER OF
SHARES NONE
BENEFICIALL
Y OWNED BY
7 SOLE DISPOSITIVE POWER
EACH
REPORTING 24,585,840
PERSON
WITH:
8 SHARED DISPOSITIVE POWER
NONE
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
24,585,840 Beneficial ownership disclaimed pursuant to Rule
13d-4
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
10.4%
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IA
** A division of Capital Research and Management Company (CRMC)
CUSIP: 36197T103 Page 2 of 5
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Schedule 13G
Under the Securities Exchange Act of 1934
Amendment No.
Item 1(a) Name of Issuer:
GW Pharmaceuticals plc
Item 1(b) Address of Issuer's Principal Executive Offices:
Porton Down Science Park, Salisbury
Wiltshire, SP4 0JQ
United Kingdom
Item 2(a) Name of Person(s) Filing:
Capital Research Global Investors
Item 2(b) Address of Principal Business Office or, if none,
Residence:
333 South Hope Street
Los Angeles, CA 90071
Item 2(c) Citizenship: N/A
Item 2(d) Title of Class of Securities:
Ordinary Shares
Item 2(e) CUSIP Number:
36197T103
Item 3 If this statement is filed pursuant to sections 240.13d-1(b)
or 240.13d-2(b) or (c), check whether the person filing is a:
(e) [X] An investment adviser in accordance with
section 240.13d-1(b)(1)(ii)(E).
Item 4 Ownership
Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer
identified in Item 1.
(a) Amount beneficially owned:
(b) Percent of class:
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
(ii) Shared power to vote or to direct the vote:
(iii) Sole power to dispose or to direct the disposition of:
(iv) Shared power to dispose or to direct the disposition of:
See page 2
Capital Research Global Investors is deemed to be the
beneficial owner of 24,585,840 shares or 10.4% of the
236,402,355 shares believed to be outstanding as a result of
CRMC acting as investment adviser to various investment
companies registered under Section 8 of the Investment Company
Act of 1940.
CUSIP: 36197T103 Page 3 of 5
All shares reported are held in the form of American Depositary
Shares, each representing 12 Ordinary Shares.
Item 5 Ownership of Five Percent or Less of a Class. If this
statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following: [ ]
Item 6 Ownership of More than Five Percent on Behalf of Another
Person: One or more clients of Capital Research Global
Investors have the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of,
the Ordinary Shares of GW Pharmaceuticals plc. Capital
Research Global Investors holds more than five percent of the
outstanding Ordinary Shares of GW Pharmaceuticals plc as of
July 31, 2014 on behalf of each of the following client(s):
SMALLCAP World Fund, Inc.
Item 7 Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company or Control Person: N/A
Item 8 Identification and Classification of Members of the Group:
N/A
Item 9 Notice of Dissolution of Group: N/A
Item 10 Certification
By signing below, I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and
are held in the ordinary course of business and were not
acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose
or effect.
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
Date: August 8, 2014
Signature: Timothy D. Armour***
Name/Title: Timothy D. Armour - Senior Vice President
Capital Research Global Investors
CUSIP: 36197T103 Page 4 of 5
***By /s/ Herbert Y. Poon
Herbert Y. Poon
Attorney-in-fact
Signed pursuant to a Power of Attorney dated January 28, 2014
included as an Exhibit to Schedule 13G filed with the
Securities and Exchange Commission by Capital Research Global
Investors on February 10, 2014 with respect to Allergan, Inc.
CUSIP: 36197T103 Page 5 of 5